Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?

Subrata Ghosh

doi:10.1093/ecco-jcc/jjaf144

Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?

Subrata Ghosh

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjaf144
Publication status	Published - 2025

Keywords

Medicine
Inflammatory bowel disease
Ulcerative colitis
Crohn's disease
Disease
Vedolizumab
Dosing
Intensive care medicine
Infliximab
Clinical trial
Concomitant
Ustekinumab
Psoriasis
Internal medicine
Immunology

Access to Document

10.1093/ecco-jcc/jjaf144

https://openalex.org/W4412828886Licence: CC BY-NC-ND

Cite this

@article{b2bc827c1e464013a5373ad6414b03b1,

title = "Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?",

keywords = "Medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Disease, Vedolizumab, Dosing, Intensive care medicine, Infliximab, Clinical trial, Concomitant, Ustekinumab, Psoriasis, Internal medicine, Immunology",

author = "Subrata Ghosh",

year = "2025",

doi = "10.1093/ecco-jcc/jjaf144",

language = "English",

journal = "Journal of Crohn's and Colitis",